Yes, enhanced monitoring is necessary including glucose parameters every 3 months, comprehensive metabolic panels every 36 months, periodic IGF-1 levels, and clinical surveillance for gastrointestinal symptoms, gallbladder disease, and growth hormone-related effects
References 1 BergengrenOPekalaKRMatsoukasKFainbergJMungovanSFBrattOet al
He sees the increasing number of retractions as a good thing
Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome
This approach is particularly useful for patients interested in the metabolic benefits of GLP-1slike improved insulin sensitivity and glucose controlwithout necessarily pursuing significant weight loss. While theres an overwhelming amount of anecdotal evidence, there isnt any clinical data to validate that microdosing semaglutide medication works
Receptor Crosstalk and Pathway Interactions The interaction between IGF-1R and myostatin-ActRIIB pathways is not strictly independent